Anti-ChAT-SAP [IT-42, KIT-42]

Name: Anti-ChAT-SAP [IT-42, KIT-42]
SKU: IT-42
Availability: InStock

a tool for eliminating cells that express choline acetyltransferase in multiple species; targeted via the affinity-purified rabbit polyclonal antibody to ChAT, eliminated via saporin

Size

Clear

SKU: IT-42 Category: Targeted Toxins Quantity: Individual 25 ug, Individual 100 ug, Individual 250 ug, Individual 1 mg, Kit w/controls 25 ug, Kit w/controls 100 ug, Kit w/controls 250 ug | Antibody Type: affinity-purified, Polyclonal | Host: rabbit | Reactivity: guinea pig, human, mouse, pig, rabbit, rat | Conjugate: saporin | Usage: eliminates cells, retrograde transport |

Choline acetyltransferase (ChAT) catalyzes the synthesis of the neurotransmitter acetylcholine (ACh) from choline and acetyl-CoA in cholinergic neurons. ChAT serves as a specific marker for cholinergic neurons in both peripheral and central nervous systems. Dysfunction of cholinergic neurons underlies aspects of clinical symptoms found in neurological and psychiatric disorders such as Alzheimer’s disease, Down and Rett syndromes.

Anti-ChAT-SAP is a chemical conjugate of the affinity-purified rabbit polyclonal antibody to ChAT and the ribosome-inactivating protein, saporin. It specifically eliminates cells that express choline acetyltransferase.

Anti-ChAT-SAP is available individually (Cat. #IT-42) or as a kit (Cat. #KIT-42) which includes Anti-ChAT-SAP and Rabbit IgG-SAP (Cat. #IT-35).

keywords: ChAT, Choline Acetyltransferase, ACh, Acetylcholine, antibody, Anti-ChAT, Anti-Choline Acetyltransferase, Acetyl-CoA, Cholinergic interneurons of dorsal striatum, cholinergic, neurons, CNS, neurological disorder, psychiatric, Alzheimer’s disease, Down syndrome, Rett syndrome, brain, neuroscience, cholinergic system

Reviews

There are no reviews yet.

Be the first to review “Anti-ChAT-SAP [IT-42, KIT-42]”

You must be logged in to post a review.

View Data Sheet

An acetylcholine-dopamine interaction in the nucleus accumbens and its involvement in ethanol’s dopamine-releasing effect.

Loftén A, Adermark L, Ericson M, Söderpalm B (2021) An acetylcholine-dopamine interaction in the nucleus accumbens and its involvement in ethanol's dopamine-releasing effect. Addict Biol 26(3):e12959. doi: 10.1111/adb.12959
Summary: Basal extracellular levels of dopamine within the nucleus accumbens are not sustained by muscarinic acetylcholine, whereas accumbal Cholinergic interneurons-ACh are involved in mediating ethanol-induced dopamine release.

Usage: Anti-ChAT-SAP or Rabbit IgG-SAP were infused at a flow rate of 0.05 μl/min for 10 min giving a total volume of 0.5 μl.
Related Products: Anti-ChAT-SAP (Cat. #IT-42), Rabbit IgG-SAP (Cat. #IT-35)

Striatal cholinergic interneurons exert inhibition on competing default behaviours controlled by the nucleus accumbens and dorsolateral striatum.

Ashkenazi SL, Polis B, David O, Morris G (2021) Striatal cholinergic interneurons exert inhibition on competing default behaviours controlled by the nucleus accumbens and dorsolateral striatum. Eur J Neurosci 53(7):2078-2089. doi: 10.1111/ejn.14873
Objective: To determine whether cholinergic interneurons contribute to the competition between both ventral and dorsolateral control systems.

Summary: Findings indicate a central role of cholinergic interneurons in regulating motivational impact on striatally controlled behaviors.

Usage: Anti-ChAT-SAP was diluted to 0.5 μg/μl in phosphate buffer saline and 0.5 μl were injected in each injection site.
Related Products: Anti-ChAT-SAP (Cat. #IT-42)

Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome.

Xu M, Kobets A, Du J, Lennington J, Li L, Banasr M, Duman R, Vaccarino F, DiLeone R, Pittenger C (2015) Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome. Proc Natl Acad Sci U S A 112:893-898. doi: 10.1073/pnas.1419533112

Summary: Postmortem studies of Tourette syndrome patients has revealed a reduction in the number of specific striatal interneurons. The authors explored the hypothesis that this neuronal deficit is enough to produce the symptoms of Tourette syndrome in mice. Animals received 90-ng injections of Anti-ChAT-SAP (Cat. #IT-42) into the striatum. Rabbit IgG-SAP (Cat. #IT-35) was used as a control. The data suggest that loss of the striatal interneurons is enough to produce some, but not all, of the symptoms caused by Tourette syndrome.

Related Products: Anti-ChAT-SAP (Cat. #IT-42), Rabbit IgG-SAP (Cat. #IT-35)

browse all references for this product | back to top

Rabbit IgG-SAP (Cat. #IT-35)